Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 3/20 | 0.50 |
| ▸ | CA1 | P00915 | 2/20 | 0.50 |
| ▸ | CA12 | O43570 | 2/20 | 0.50 |
| ▸ | CA9 | Q16790 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.45 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.41 |
| ▸ | UBA2 | Q9UBT2 | 1/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.40 |
| ▸ | IDO1 | P14902 | 1/20 | 0.39 |
| ▸ | MMP2 | P08253 | 1/20 | 0.39 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.38 |
| ▸ | CA3 | P07451 | 1/20 | 0.38 |
| ▸ | CA6 | P23280 | 1/20 | 0.38 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9172643 | 0.83 | LOXL2 (0.48) | CA2CA1CA12CA9MAPT | |
| SCHEMBL1800038 | 0.78 | CYP2A6 (0.52) | CA2CA1CA12CA9MAPT | |
| SCHEMBL5885533 | 0.77 | LMNA (0.48) | MAPTALDH1A1IDO1LMNAHTT | |
| SCHEMBL11741377 | 0.76 | MAPT (0.58) | CA2CA1CA12CA9MAPT | |
| SCHEMBL7520952 | 0.75 | ABCB1 (0.50) | CA2CA1MAPTLOXL2CYP2A6 | |
| SCHEMBL4225554 | 0.74 | CA12 (0.53) | CA2CA1CA12CA9MAPT | |
| SCHEMBL16274245 | 0.74 | CA2 (0.44) | CA2CA1CA12CA9MAPT | |
| SCHEMBL17076659 | 0.74 | CA12 (0.58) | CA2CA1CA12CA9MAPT | |
| SCHEMBL5516545 | 0.74 | ALDH1A1 (0.44) | CA2CA1MAPTLOXL2CYP2A6 | |
| SCHEMBL11078522 | 0.74 | MAPT (0.53) | CA2CA1CA12CA9MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119161324-A | Methods and compounds for restoring mutant p53 function | 皮姆维制药公司 | 2024-12-20 | — | — | CN | disclosed |
| CN-117865869-A | Method for synthesizing 1-trifluoromethyl indole compound by taking 2-alkynyl aromatic amine as raw material | 江南大学 | 2024-04-12 | — | — | CN | disclosed |
| CN-117865870-A | Method for synthesizing 1-trifluoromethyl indole compound by taking 2-alkynyl aryl isothiocyanate as raw material | 江南大学 | 2024-04-12 | — | — | CN | disclosed |
| WO-2022247676-A1 | COMPOUND WITH DIPYRROLOPYRIDINE STRUCTURE, AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | 南京康屹生物医药中心(有限合伙) | 2022-12-01 | — | — | WO | disclosed |
| WO-2022247676-A1 | COMPOUND WITH DIPYRROLOPYRIDINE STRUCTURE, AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | 南京康屹生物医药中心(有限合伙) | 2022-12-01 | — | — | WO | disclosed |
| CN-115385911-A | Compound with dipyrrolopyridine structure, preparation method and medical application | 南京康屹生物医药中心(有限合伙) | 2022-11-25 | — | — | CN | disclosed |
| US-20220213062-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | PMV PHARMACEUTICALS, INC. | 2022-07-07 | — | — | US | disclosed |
| US-11339141-B2 | Methods and compounds for restoring mutant p53 function | PMV PHARMACEUTICALS, INC. (US) | 2022-05-24 | — | — | US | disclosed |
| CN-113292561-A | Compound with dipyrrolopyridine structure, preparation method and medical application | 中国药科大学 | 2021-08-24 | — | — | CN | disclosed |
| US-20210002252-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | PMV PHARMACEUTICALS, INC. | 2021-01-07 | — | — | US | disclosed |
| US-7005437-B2 | Substituted aryl and heteroaryl derivatives, the preparation thereof and the use therof as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2006-02-28 | — | — | US | disclosed |
| EP-1140802-B1 | SUBSTITUTED ARYL AND HETEROARYL DERIVATIVES, THEIR PRODUCTION AND THEIR USE AS MEDICINES | BOEHRINGER INGELHEIM PHARMA (DE) | 2004-03-17 | — | — | EP | disclosed |
| US-20030045712-A1 | Substituted aryl and heteroaryl derivatives, the preparation thereof and the use therof as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2003-03-06 | — | — | US | disclosed |
| US-6479524-B1 | TO PROLONG THE THROMBIN TIME | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2002-11-12 | — | — | US | disclosed |
| EP-1140802-A1 | SUBSTITUTED ARYL AND HETEROARYL DERIVATIVES, THEIR PRODUCTION AND THEIR USE AS MEDICINES | BOEHRINGER INGELHEIM KG (DE) | 2001-10-10 | — | — | EP | disclosed |
| WO-2000035859-A1 | SUBSTITUTED ARYL AND HETEROARYL DERIVATIVES, THEIR PRODUCTION AND THEIR USE AS MEDICINES | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2000-06-22 | — | — | WO | disclosed |
| EP-0426666-A1 | SUBSTITUTED QUINAZOLINONES AS ANTICANCER AGENTS | WARNER-LAMBERT COMPANY (US) | 1991-05-15 | — | — | EP | disclosed |
| US-4857530-A | THYMIDYLATE SYNTHASE INHIBITORS | WARNER-LAMBERT COMPANY (US) | 1989-08-15 | — | — | US | disclosed |
| EP-0316657-A1 | Substituted quinazolinones as anticancer agents | WARNER-LAMBERT COMPANY (US) | 1989-05-24 | — | — | EP | disclosed |
| WO-1989004307-A1 | SUBSTITUTED QUINAZOLINONES AS ANTICANCER AGENTS | WARNER-LAMBERT COMPANY (US) | 1989-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11339141-B2 | Methods and compounds for restoring mutant p53 function | TP53, TP53BP1, KRAS | CA2 3501/4885CA1 2828/4885CA12 3754/4885 |
| US-20220213062-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | TP53, TP53BP1, KRAS | CA2 3501/4885CA1 2828/4885CA12 3754/4885 |
| US-20210002252-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | TP53, TP53BP1, KRAS | CA2 3501/4885CA1 2828/4885CA12 3754/4885 |
| US-20030045712-A1 | Substituted aryl and heteroaryl derivatives, the preparation thereof and the use therof as pharmaceutical compositions | F2, F12, F3 | CA2 927/4885CA1 1303/4885CA12 1846/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.